

**NAFLD EASD Study Group  
Spring Meeting  
June 3-4, 2021 – 5:00 PM (Rome)  
Sexual Dimorphism And FGF Signaling In NAFLD**

**Thursday June 3, 5:00-7:00 PM (Central European Time - CET)**

**PPAR $\alpha$  as a sexually dimorphic drug target in NAFLD**

*Hervé GUILLOU (Toxalim, INRAE, Toulouse, France)*

**Sex-discriminating factor in hepatic metabolism**

*Adriana MAGGI (Università di Milano, Italy)*


**Friday June 4, 5:00-7:00pm (Italian time)**

**Fibroblast growth factors for NASH treatment»**

Stephen HARRISON (Pinnacle Clinical Research, San Antonio, TX, USA)

**FGF19 and FGF21 for the Treatment of NASH—Two Sides of a Coin?**

Birgitte ANDERSEN (NovoNordisk, Copenhagen, DK)



# **NAFLD EASD Study Group Spring Meeting June 3-4, 2021 – 5:00 PM (Rome) Sexual Dimorphism And FGF Signaling In NAFLD**

## **Organising committee**

Cathernine Postic (France)

Amalia Gastaldelli (Italy)

Caroline Bonner (France)

Chiara Saponaro (France)

## **Meeting Secretariat**

Lucrecia Mota (Office support)

Yannick Carbonneux (Graphic Designer)

Christophe Montois & Valery Gymr (website)

## **Steering committee**

Amalia Gastaldelli (Italy) Chair

Hannele Yki-Jarvinen (Finland) Vice-Chair

Christopher Byrne (UK)

Leanne Hodson (UK)

Paula Macedo (Portugal)

Stefano Romeo (Sweden)

Gianluca Svegliati-Baroni (Italy)

With the kind support of

